U.S. Multiple Myeloma Market


Regular Price: USD 4,950.00

Special Price USD 3,465.00

30% OFF

* Required Fields

Regular Price: USD 4,950.00

Special Price USD 3,465.00


Be the first to review this product

The U.S. Multiple Myeloma Market is a rapidly progressing field that is set to generate over $3 billion in revenue in the coming years. The market has witnessed unprecedented growth with the launch of three new drugs. The dynamics of this market are changing rapidly and the forecast through 2013 highlights the major changes. This study includes patient forecasts, pipeline analysis and individual product revenue forecasts.

Table of Contents

U.S. Multiple Myeloma Market, Executive SummaryExecutive SummaryExecutive SummaryU.S. Multiple Myeloma Market, Market IntroductionResearch Scope and MethodologyScope and SegmentationResearch MethodologyBlood Cancer OverviewBlood Cancer BiologyBlood Cancer DefinitionsMultiple Myeloma OverviewEtiologyStaging and Prognostic FactorsTreatment OverviewPatient ForecastsPrevalenceIncidenceMortalityStagingGeneral Market TrendsIndustry Challenges and StrategiesMarket DriversU.S. Multiple Myeloma Market, Product and Pipeline AnalysisApproved Product AnalysisChemotherapy Product AnalysisSteroid Product AnalysisInterferon Product AnalysisImmunomodulatory Product AnalysisPipeline AnalysisChemotherapy Pipeline AnalysisTargeted Therapy Late Stage Pipeline AnalysisTargeted Therapy Early Stage Pipeline AnalysisSupportive Product PipelineU.S. Multiple Myeloma Market, Competitive AnalysisIntroductionTreatment TrendsMarket Engineering MeasurementsCommon Drug RegimensDrug PricesMarket Revenue ForecastsTotal Market Revenue ForecastsFirst-line HSCT Eligible Revenue ForecastsFirst-line HSCT Non-Eligible Revenue ForecastsSecond-line Revenue ForecastsThird-line+ Revenue ForecastsMarket Share AnalysisProduct Revenue ForecastsAlkeranDoxilRevlimidThalomidVelcadeTanespimycinZIO-101PerifosineU.S. Multiple Myeloma Market, AppendixDecision Support DatabasesPhysiciansGovernment Healthcare ExpenditurePrivate Healthcare ExpenditurePharmaceutical R&D ExpenditurePercent Pharmaceutical R&D Expenditure

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.